161. |
162. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodcaErik Brecelj, Vesna Zadnik, Neva Volk, Mateja Krajc, Ana Blatnik, Ksenija Strojnik, Nina Boc, Yasmin Marianna Hunt, Gorana Gašljević, Jera Jeruc, Srdjan Novaković, Marko Boc, Franc Anderluh, Martina Reberšek, Borut Štabuc, Irena Oblak, Janja Ocvirk, Ana Jeromen, Zvezdana Hlebanja, Tanja Mesti, Marija Ignjatović, Nežka Hribernik, Ibrahim Edhemović, Gašper Pilko, Rok Petrič, Ajra Šečerov Ermenc, Nada Rotovnik-Kozjek, Vaneja Velenik, Sonja Kramer, Maja Ebert Moltara, Jernej Benedik, 2021, strokovni članek Ključne besede: adenokarcinom želodca, priporočila, prebavni trakt, multidisciplinarno zdravljenje
Objavljeno v DiRROS: 16.12.2021; Ogledov: 1205; Prenosov: 536
 Celotno besedilo (355,48 KB)
Gradivo ima več datotek! Več... |
163. |
164. Infiltration processes in karst aquifers affected by large-scale forest disturbancesUrša Vilhar, Mitja Ferlan, Janez Kermavnar, Erika Kozamernik, Aleksander Marinšek, Metka Petrič, Tanja Pipan, Daniel Žlindra, Nataša Ravbar, 2021, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: karst hydrogeology, global environmental changes, large-scale forest disturbances, aquifer recharge, water monitoring
Objavljeno v DiRROS: 03.12.2021; Ogledov: 1168; Prenosov: 716
Celotno besedilo (277,79 KB)
Gradivo ima več datotek! Več... |
165. |
166. Priročnik za določanje korenin olesenelih rastlinTanja Mrak, Jožica Gričar, Peter Železnik, Hojka Kraigher, 2016, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: določevalni ključi, znanstvene monografije, morfologija rastlin, anatomija rastlin, drobne korenine, EUFORINNO
Objavljeno v DiRROS: 03.11.2021; Ogledov: 773; Prenosov: 0 |
167. Ectomycorrhiza between Scleroderma Areolatum Ehrenb. and Fagus sylvatica L.Tanja Mrak, Katja Kühdorf, Tine Grebenc, Ines Štraus, Marko Bajc, Nada Žnidaršič, Babette Münzenberger, Hojka Kraigher, 2015, objavljeni povzetek znanstvenega prispevka na konferenci Objavljeno v DiRROS: 03.11.2021; Ogledov: 855; Prenosov: 281
Celotno besedilo (1,05 MB) |
168. |
169. Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European centerMarija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, izvirni znanstveni članek Povzetek: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Objavljeno v DiRROS: 12.10.2021; Ogledov: 978; Prenosov: 302
 Povezava na datoteko |
170. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodca2021, druge monografije in druga zaključena dela Povzetek: V Sloveniji vsako leto zboli zaradi raka želodca okrog 450 bolnikov, od tega ima tri četrtine bolnikov ob postavitvi diagnoze razširjeno ali razsejano bolezen. Zato je pomembno, da imamo razvito sodobno multidisciplinarno zdravljenje. Onkološki inštitut je na poti pridobitve evropske onkološke akreditacije, ki jo podeljuje priznana Evropska organizacija onkoloških inštitutov (OECI), katere član je tudi Onkološki inštitut Ljubljana. Namen tega projekta je razvoj kliničnih poti, ki bodo omogočile celostno obravnavo bolnikov z rakom. Slovenskih priporočil za zdravljenje adenokarcinoma želodca trenutno nimamo, zato smo bili primorani sprejeti te, ki jim bomo sledili na Onkološkem inštitutu. V teh priporočilih, zaradi drugačne narave bolezni, ni zajeto zdravljenje raka ezofagogastričnega stika.
Ključne besede: rak želodca, adenokarcinom, onkološko zdravljenje, priporočila
Objavljeno v DiRROS: 14.09.2021; Ogledov: 1470; Prenosov: 383
Celotno besedilo (983,68 KB) |
